FOXP1 and diffuse large B-cell lymphoma: In diffuse large B-cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma type) treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone), increased miR-181a expression prolonged progression free survival (PFS) by suppression of FOXP1 and O6-methylguanine DNA methyltransferase (MGMT) while increased miR-18a levels led to shorter overall survival (OS) and high miR-222 expression to shorter PFS[37].